Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance

Bibliography

• Estabrook RW. Cytochrome P450: from a single protein to a family of proteins – with some personal reflections. In: Ioannides C, editor, Cytochromes P450: metabolic and toxicological aspects. CRC Press, Inc., Boca Raton, Florida; 1996. p. 3-28
   Google Scholar
• Caldwell J. The significance of phase II (conjugation) reactions in drug disposition and toxicity. Life Sci 1979;24:571-8
   PubMed Web of Science ®Google Scholar
• Rudorfer M, Potter W. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 1997;7:273-312
   PubMed Web of Science ®Google Scholar
• Court MH, Greenblatt DJ. Biochemical basis for deficient paracetamol glucuronidation in cats: an interspecies comparison of enzyme constraint in liver microsomes. J Pharm Pharmacol 1997;49:446-9
   PubMed Web of Science ®Google Scholar
• Court M, Greenblatt DJ. Molecular basis for deficient acetaminophen glucuronidation in cats: an interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol 1997;53:1041-7
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. Metabolites in Safety Testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 2009;22:267-79
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 2006;19:1570-9
   PubMed Web of Science ®Google Scholar
• Clarke NJ, Rindgen D, Korfmacher WA, Cox KA. Systematic LC/MS Metabolite Identification in drug discovery. Anal Chem 2001;73:430-9
   PubMed Web of Science ®Google Scholar
• Kostiainen R, Kotiaho T, Kuuranne T, Auriola S. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 2003;38:357-72
   PubMed Web of Science ®Google Scholar
• Baillie TA, Cayen MN, Fouda H, Drug metabolites in safety testing. Toxicol Appl Pharmacol 2002;182:188-96
   PubMed Web of Science ®Google Scholar
• Hastings KL, El-Hage J, Jacobs A, Letter to the editor. Toxicol Appl Pharmacol 2003;190:91-2
   PubMed Web of Science ®Google Scholar
• The US FDA. Guidance for Industry: Safety Testing of Drug Metabolites. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf. 2008
   Google Scholar
• ICH. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available from: http://www.ich.org/LOB/media/MEDIA5544.pdf. 2009
   Google Scholar
• The US FDA. Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals ICH Revision 1. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf. 2010
   Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-16
   PubMed Web of Science ®Google Scholar
• Yu C, Chen CL, Gorycki FL, Neiss TG. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. Rapid Commun Mass Spectrom 2007;21:497-502
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 2009;22:357-68
   PubMed Web of Science ®Google Scholar
• Zhu M, Ma L, Zhang D, Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab Dispos 2006;34:1722-33
   PubMed Web of Science ®Google Scholar
• Pelander A, Tyrkko E, Ojanpera I. In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening. Rapid Commun Mass Spectrom 2009;23:506-14
   PubMed Web of Science ®Google Scholar
• Baillie TA. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem Res Toxicol 2009;22:263-6
   PubMed Web of Science ®Google Scholar
• Leclercq L, Cuyckens F, Mannens GSJ, Which human metabolites have we MIST? retrospective analysis, practical aspects, and perspectives For metabolite identification and quantification in pharmaceutical development. chemical research in toxicology 2009;22:280-93
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang D, Ray K. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom 2003;38:414-20
   Google Scholar
• Tiller PR, Yu S, Bateman KP, Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. Rapid Commun Mass Spectrom 2008;22:3510-16
   PubMed Web of Science ®Google Scholar
• Hop CECA, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 1998;87:901-3
   PubMed Web of Science ®Google Scholar
• Baillie TA. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 2006;19:889-93
   PubMed Web of Science ®Google Scholar
• Guengerich FP, MacDonald JS. Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 2007;20:344-69
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007;47:513-39
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92
   PubMed Web of Science ®Google Scholar
• Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the "Danger Hypothesis" and innate immune system. Chem Res Toxicol 1999;12:387-95
   PubMed Web of Science ®Google Scholar
• Smith DA, Obach RS. Seeing through the MIST: abundance versus percentage. commentary on metabolite in safety testing. Drug Metab Dispos 2005;33:1409-17
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin Drug Metab Toxicol 2005;1:23-31
   PubMedGoogle Scholar
• Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 2008;4:1021-33
   PubMed Web of Science ®Google Scholar
• Walker GS, O'Connell T. Comparison of LC-NMR and conventional NMR for structure elucidation in drug metabolism studies. Expert Opin Drug Metab Toxicol 2008;4:1295-305
   PubMed Web of Science ®Google Scholar